Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, May 7 () Roche Diagnostics India on Thursday said it has received import licence from the Central Drugs Standard Control Organisation (CDSCO) for its Elecsys Anti-SARS-CoV-2 test kit and is readying to bring it to India. The import licence has been issued by the drug regulator due to the emergency health situation in public interest, Roche Diagnostics India said in a statement. "From bringing the globally used tests to the country in record time to establishing the disease control measures by creating COVID-19 diagnostic hubs..., the Indian government and the state governments have been collaborating with various sections of the healthcare system to manage the situation," Roche Diagnostics India MD Shravan Subramanyam said. Laboratory-based immunodiagnostic testing will complement the existing reverse transcription polymerase chain reaction (RT-PCR) solutions to possibly ascertain coronavirus-related immunity among patients and all those who want to 'go back to work' to bring the health and economic activity back to normalcy, he added. The test can support priority screening of high-risk groups, such as healthcare workers, delivery service providers, or food supply workers who might already have been exposed and developed an immune response, the statement said. AKT HRS

Roche Diagnostics India gets import licence for COVID-19 antibody test kit from CDSCO

<ul><li>Vijaya Diagnostic IPO is the second diagnostic lab chain to list publicly in recent times after <keyword id="11265915" type="General" weightage="20" keywordseo="krsnaa-diagnostics" source="Orion">Krsnaa Diagnostics</keyword>.</li><li>The IPO of the company will open on September 1 and close on September 3 with a price band of ₹522 to ₹531 per share.</li><li>The company aims to deepen its presence in Andhra Pradesh, Telangana and is looking to acquire good diagnostic firms in eastern India to explore business opportunities there, said Sunil Chandra Kondapally, executive director at Vijaya Diagnostic in an interview with Business Insider.</li></ul>Vijaya Diagnostic, which is to launch its initial public offering (IPO) on Wednesday, is looking to acquire more diagnostics firms in eastern India to expand its business. The company has a strong presence in southern India in the states of Andhra Pradesh and Telangana and now looks to expand in some eastern states primarily through acquisition. The company offers a “one-stop solution” for pathology and radiology testing services through its 80 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. “We are a debt free company and due to our strong margin we also have liquidity on the balance sheet. We have built up a ₹250 crore cash on the book so priority is to use that corpus for the growth of the business. So we are definitely open for acquisition opportunities in any markets of interest,” said Sunil Chandra Kondapally, executive director at <keyword id="182111" type="General" weightage="20" keywordseo="vijaya-diagnostics" source="Orion">Vijaya Diagnostics</keyword> in an interview with Business Insider. The diagnostics company’s business model is different from that of similar listed diagnostics companies -- <keyword id="122279" type="General" weightage="20" keywordseo="metropolis" source="Orion">Metropolis</keyword> Lab, <keyword id="122277" type="General" weightage="20" keywordseo="dr-lal-pathlabs" source="Orion">Dr Lal PathLabs</keyword>. “Right from inception our focus has been to offer both radiology, pathology and imaging all under one roof so that the patient does not have to visit any other place. In that sense we are quite different as all our centres offer these services. 93% of our revenue comes from business-to-consumer (B2C) business whereas other players have more of [a] business-to-business (B2B) model,” added Kondapally. Further, the company is in hunt for diagnostics firms that have a similar kind of B2C business model with brand visibility. Vijaya Diagnostic Centre’s IPO is an entire offer for sale (OFS) from existing promoters of 3.56 crore equity shares. The company’s founder Dr. S. Surendranath Reddy will sell 50.98 lakh shares, Karakoram Limited will sell up to 2.94 crore shares and Kedaara Capital will sell partial stake of up to 11.02 lakh shares. The private equity investor and the promoter company are not exiting completely from the firm as post-issue Kedaara Capital will hold 10% stake in the company and the promoter will have 55% shareholding and remaining 35% will be available publicly for investors. Vijaya Diagnostic says it has a market share of 7% in its home market -- Andhra Pradesh, Telangana. Going forward, it looks to capture close to 20% of it. The market size of the business in both states is worth ₹5,100 crore, Kondapally said in the interview. The diagnostics company’s revenue and profit have also been increasing consistently. <table style="border-width: initial; border-style: none;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Particulars </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">FY21 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">FY20 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">FY19 </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Net profit (in ₹ crore) </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">84.9 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">62.5 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">46.2 </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Revenue (in ₹ crore) </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">388.5 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">354.1 </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">302.9 </td></tr></tbody><tbody></tbody></table> The latest acquisition by the company in east India was listed firm Medinova Diagnostics Services in 2014, which had established centres in Kolkata. The subsidiary now contributes 3.7% (June quarter) of revenue to the company. Hence, Vijaya Diagnostic plans to add more centres in that region. Over 96% of the Vijaya Diagnostic’s revenue comes from Hyderabad, the rest of Telangana, and the Andhra Pradesh region. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/airtels-board-approves-raising-funds-of-up-to-21000-crore/articleshow/85737069.cms">Airtel’s board approves raising funds of up to ₹21,000 crore</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/dcga-extends-ban-on-international-passenger-flights-till-september-30/articleshow/85735218.cms">DCGA extends ban on international passenger flights till September 30</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/sports/news/tokyo-paralympics-paddler-bhavinaben-patel-wins-historic-silver-in-womens-singles-tables-tennis/articleshow/85731500.cms">Tokyo Paralympics: Paddler Bhavinaben Patel wins historic silver in women's singles tables tennis</a>

IPO-bound Vijaya Diagnostic is planning more acquisitions in east India to expand business

Some 13 African countries have reported 6,883 <keyword id="13971396" type="General" weightage="20" keywordseo="monkeypox-cases" source="Orion">monkeypox cases</keyword> since the start of 2022, the <keyword id="9260976" type="General" weightage="50" keywordseo="africa-centers-for-disease-control-and-prevention" source="Orion">Africa Centers for Disease Control and Prevention</keyword> (<keyword id="12925" type="General" weightage="80" keywordseo="africa" source="Orion">Africa</keyword> <keyword id="6379474" type="General" weightage="80" keywordseo="cdc" source="Orion">CDC</keyword>) has disclosed. According to data released by the Africa CDC, 173 deaths and a case fatality ratio of 2.5 per cent have also been registered during the same period. The continental health agency noted that out of the 6,883 cases, 5,992 are suspected cases while 891 are confirmed cases, Xinhua news agency reported. The <keyword id="7616951" type="General" weightage="100" keywordseo="monkeypox" source="Orion">monkeypox</keyword> cases were reported from eight endemic and five non-endemic countries. The eight endemic countries are Benin, Cameroon, Central African Republic, Congo, Democratic Republic of Congo, Ghana, Liberia and Nigeria; the five non-endemic countries are Egypt, Morocco, Mozambique, South Africa and Sudan, according to the Africa CDC. Following the announcement by the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword> that declared monkeypox a global public health emergency of international concern in July this year, the Africa CDC has been calling on African countries to strengthen laboratory diagnostic capacities and genomic sequencing capacity for monkeypox. The continental health body also called on African states to develop and distribute both general and tailored risk communication messages for communities and vulnerable population groups. Monkeypox, first detected in laboratory monkeys in 1958, is assumed to transmit from wild animals such as rodents to people, or from human to human. It is a rare viral disease usually transmitted through body fluids, respiratory droplets and other contaminated materials. The infection usually results in fever, rash and swollen lymph nodes. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/musk-is-now-twitter-boss-fires-indian-origin-ceo-agrawal-other-top-execs/articleshow/95134427.cms">Musk is now Twitter boss, fires Indian-origin CEO Agrawal, other top execs</a> <a href="https://www.businessinsider.in/international/news/meet-the-first-indian-first-lady-of-uk-akshata-murty/articleshow/95095250.cms">Meet the first Indian first lady of UK - Akshata Murty</a>

African countries have reported 6,883 Monkeypox cases, 173 deaths in 2022

New Delhi, Apr 4 () The government on Saturday put curbs on exports of diagnostic kits with a view to discourage shipments amid the coronavirus outbreak. "The export of diagnostic kits (diagnostic or laboratory reagents on a backing, preparation diagnostic or laboratory reagents)... is restricted with immediate effect," the Directorate General of Foreign Trade (DGFT) said in a notification. The move would help in dealing with the Covid-19 crisis as these kits are required for testing of patients. Earlier, exports of these products were allowed without any restrictions. Putting them under the restricted category would mean that an exporter will now require a licence from the DGFT for outbound shipments. RR ABMABM

Govt puts curbs on exports of diagnostic kits with immediate effect

<div class="KonaFilter image-container"><div class="image"></div></div>
President Barack Obama made a statement from the White House on Monday after meeting with his advisors to discuss the Ebola epidemic in West Africa. Obama said confronting the disease at its source and preventing an outbreak in the US are a "top national security priority."
"It is very important for us to make sure that we are treating this the same way that we would treat any other significant national security threat," Obama said. "And that's why we've got an all-hands-on-deck approach - from DOD to public health to our development assistance, our <keyword id="41551" type="ENTERTAINMENT" weightage="60" keywordseo="science">science</keyword> teams - everybody is putting in time and effort to make sure that we are addressing this as aggressively as possible."
Though he emphasized the dangers posed by the disease, Obama stressed the possibility of an Ebola outbreak on American soil is "extremely low."
"I know that the American people are concerned about the possibility of an Ebola outbreak, and Ebola is a very serious disease. And the ability of people who are infected who could carry that across borders is something that we have to take extremely seriously," Obama said. "At the same time, it is important for Americans to know the facts, and that is that because of the measures that we've put in place, as well as our world-class health system and the nature of the Ebola virus itself - which is difficult to transmit - the chances of an Ebola outbreak in the United States is extremely low."
On Sept. 30, the first imported case of Ebola in the US was identified when a man who had traveled from Liberia was diagnosed with the virus in Texas. Other Ebola patients have been brought to the US for treatment after being diagnosed in Africa. 
Soon after the president spoke, the White House released a fact sheet detailing the US government's response to Ebola. It identified "four key goals" of the American strategy to confront the virus:
<ul>
<li>"Controlling the epidemic at its source in West Africa;</li>
<li>Mitigating second-order impacts, including blunting the economic, social, and political tolls in the region;</li>
<li>Engaging and coordinating with a broader global audience; and,</li>
<li>Fortifying global health security infrastructure in the region and beyond, including within the United States."</li>
</ul>
The White House fact sheet also described some elements of the $350 million anti-Ebola effort launched by Obama last month including $111 million in humanitarian aid, "130 civilian medical, healthcare, and disaster response experts from multiple U.S. government departments and agencies" and 350 military personnel who have been deployed to West Africa, and deliveries of equipment. Overall, the fact sheet indicated the US is "prepared to devote more than $1 billion to the whole-of-government Ebola response effort."
Domestically, the White House said the government is working to increase diagnostic capabilities at laboratories around the country and step up screenings at airports both here and abroad. 
In his statement, Obama encouraged other countries to similarly step up their efforts to fight the epidemic. 
"I'm going to be putting a lot of pressure on my fellow heads of state and government around the world to make sure that they are doing everything that they can to join us in this effort. We've got some small countries that are punching above their weight on this, but we've got some large countries that aren't doing enough," said Obama. "And we want to make sure that they understand that this is not a disease that's going to discriminate, and this is something that all of us have to be involved in."

Obama On Ebola: 'ALL HANDS ON DECK' 

Toronto, June 11 () Scientists have found that seven out of 27 COVID-19 diagnostic tests which are currently in use may be underperforming possibly due to the novel coronavirus mutating, and have cautioned that the effectiveness of testing methods needs to be re-evaluated. According to the study, published in the journal Royal Society Open Science, many of the tests were developed early in the outbreak when the virus was first identified, and its genetic material was sequenced. The researchers from York University in Canada said it is important to re-evaluate the methods periodically to ensure they still work. "COVID-19 tests use polymerase chain reaction (PCR) assays to diagnose the virus in patients, but if those assays are mismatched due to genetic variability in the viral genome, that raises the concern that the tests may not be detecting all the circulating variants of the virus and results could be inaccurate," explained Kashif Aziz Khan, corresponding author of the study. Correcting any mismatches between the assays and the coronavirus genome may help improve the sensitivity and accuracy of some of the diagnostic tests, the researchers said in a statement. According to the scientists, the early sequencing of the genetic material of the virus allowed for the development of PCR detection protocols by multiple national organizations that were published by the World Health Organization (WHO). These tests, according to the study, use probes that bind to the viral genetic material in a patient sample and help produce several detectable copies of it -- if the person is infected with the coronavirus. However, the researchers said these tests that do not account for variations and mutations. "Given the potential for the viruses to mutate, genetic variations in the viral genome at primer/probe binding regions can result in potential mismatches and false-negative results," the scientists wrote in the study. In the current study, the researchers tested genetic variations in more than 17,000 publicly available viral genome sequences worldwide, and performed an exhaustive evaluation of 27 published diagnostic PCR assays. The analysis showed the presence of mismatches in the probe binding regions of the coronavirus genetic material in seven out of the 27 assays. "These findings are potentially important for clinicians, laboratory professionals and policy-makers as it gives them a better idea of which tests may deliver the best results, and how to ensure the tests they are using are properly matched to the virus genome," Khan said. VIS VIS

You Searched For "Regional Disease Diagnostic Laboratory" and got 6 results

Roche Diagnostics India gets import licence for COVID-19 antibody test kit from CDSCO

PTI

IPO-bound Vijaya Diagnostic is planning more acquisitions in east India to expand business

Bhakti Makwana

African countries have reported 6,883 Monkeypox cases, 173 deaths in 2022

IANS

Govt puts curbs on exports of diagnostic kits with immediate effect

PTI

Obama On Ebola: 'ALL HANDS ON DECK'

Hunter Walker

Coronavirus mutations may lead to COVID-19 diagnosis test mismatch: Study

PTI

Popular Keywords

Buying Guides